

PERSONAL INFORMATION Amalia Cornea

 Timisoara Timis, (Romania)

 0256/492885

 amalia.cornea@umft.ro

WORK EXPERIENCE

2020 – present **Assistant Professor, Senior Neurology Specialist**
2013–Present **Assistant Professor, Specialist Neurologist**
University of Medicine and Pharmacy "Victor Babes", Timisoara (Romania)

2012–2013 **Neurology Specialist - voluntary**
Spitalul Clinic Judetean de Urgenta „Pius Brinzeu” Timisoara Bulevardul Liviu Rebreanu, Nr. 156, Cod 300723, <http://www.hosptm.ro>, Timisoara (Romania)

2007–2012 **Neurology resident**
Spitalul Clinic Judetean de Urgenta „Pius Brinzeu” Timisoara Bulevardul Liviu Rebreanu, Nr. 156, Cod 300723, <http://www.hosptm.ro>, Timisoara (Romania)

2005–2006 **Internal medicine - Fellowship**
Spitalul Clinic Municipal, str. Hector nr.1, 300041, <http://www.spitalul-municipal-timisoara.ro/>, Timisoara (Romania)

EDUCATION AND TRAINING

2011–2016 **Doctor of medical sciences, specialty Neurology**
University of Medicine and Pharmacy „V. Babes”, Timisoara (Romania)

1998–2004 **Medical doctor**
University of Medicine and Pharmacy "V. Babes", Timisoara (Romania)

PERSONAL SKILLS

Mother tongue(s) Română

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	B2
German	A2	A2	A2	A2	A2
French	B1	B1	B1	A2	A2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages - Self-assessment grid

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem-solving
Proficient user	Proficient user	Proficient user	Proficient user	Proficient user

Digital skills - Self-assessment grid

Driving licence B

ADDITIONAL INFORMATION

Memberships Member of SNR (Romanian Society of Neurology)

Certifications

2017 Electrophysiology and Electromyography certification 2017, Bucuresti Romania
2011 Doppler Ecography, 2011; SUUB - Bucuresti, Romania

Courses

May 2015 – Oct 2015

- Electroencephalography course, Clinical Hospital “Alexandru Obregia”, Neurology Pediatrics Clinic (Prof. Craiu D.) (four modules one month each)
- Since Oct 2015 - EEG clinical practice in the Neurology Clinic – Emergency County Hospital Timisoara

Nov 2012 – Feb 2013

- Electrophysiology and Electromyography course - Emergency University Hospital Elias, Neurology Clinic, Bucharest (Prof. Panea C.) (two modules one month)

2011 (March)

- Ecography course Doppler – SUUB, Neurology Clinic, Bucuresti (Prof. Tiu C)

Monographies - Chapters

2012

- Amalia Cornea Mihaela Simu, (coautori) „Hipertensiunea arteriala si AVC hemoragic acut ” cap.6, caz clinic1 177-187pg din cartea „Punct si contrapunct in tensiunea arteriala-program educational al Societatii Romane de Hipertensiune 2012-2013” Maria Dorobantu (coordonator), ISBN 978-973-708-699-0, Editura Universitara „Carol Davila”, 2013

Publications

2021

- Rosca EC, Tadger P, **Cornea** A, Tudor R, Oancea C, Simu M. International HIV Dementia Scale for HIV-Associated Neurocognitive Disorders: A Systematic Review and Meta-Analysis. *Diagnostics (Basel)*. 2021 Jun 20;11(6):1124. doi: 10.3390/diagnostics11061124. PMID: 34202994; PMCID: PMC8235728.
- Rosca EC, Tudor R, **Cornea** A, Simu M. Parkinson's Disease in Romania: A Scoping Review. *Brain Sci*. 2021 May 27;11(6):709. doi: 10.3390/brainsci11060709. PMID: 34071802; PMCID: PMC8226866.
- Rosca EC, Tudor R, **Cornea** A, Simu M. Central Nervous System Involvement in Trichinellosis: A Systematic Review. *Diagnostics (Basel)*. 2021 May 25;11(6):945. doi: 10.3390/diagnostics11060945. PMID: 34070586; PMCID: PMC8227095.
- Rosca EC, Tudor R, **Cornea** A, Simu M. Parkinson's Disease in Romania: A Scoping Review Protocol. *Brain Sci*. 2021 Feb 17;11(2):251. doi: 10.3390/brainsci11020251. PMID: 33671440; PMCID: PMC7922587.

2020

- Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P,

- Cubo E, Davis TL, Iansek R, Kovács N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR. Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. *Neurodegener Dis Manag.* 2020 Sep 2. doi: 10.2217/nmt-2020-0021. Epub ahead of print. PMID: 32873195.
- Constantin VA, Szász JA, Orbán-Kis K, Rosca EC, Popovici M, **Cornea A**, Bancu LA, Ciorba M, Mihály I, Nagy E, Szatmári S, Simu M. Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients. *Neuropsychiatr Dis Treat.* 2020 Jul 28;16:1835-1844. doi: 10.2147/NDT.S256988. PMID: 32801718; PMCID: PMC7395851.
 - Rosca EC, **Cornea A**, Simu M. Montreal Cognitive Assessment for evaluating the cognitive impairment in patients with schizophrenia: A systematic review. *General Hospital Psychiatry* 2020 65:64-73 ISSN 0163-8343. <https://doi.org/10.1016/j.genhosppsy.2020.05.011>
- 2016
- A. **Cornea**, C. Dijmarescu, R. Tudor, A. Petre, M. Simu, "The prevalence and clinical profile of multiple sclerosis in Timis county Romania", *Romanian Journal of Neurology*, vol. XV, nr.3, 2016, 113-119, ISSN 1843-814 /e-ISSN 2069-6094
 - A. **Cornea**, R. Tudor, A. Petre, M. Simu, "MS treatment optimization: factors associated with poor clinical response in nabs positive patients", *Romanian Journal of Neurology*, vol. XV, nr.3, 2016, 119-126, ISSN 1843-8148 /e-ISSN 2069-6094
- 2015
- A. **Cornea**, C. Rosca, A. Petre, M. Simu, "The Epidemiology of Multiple Sclerosis in Romania and Across Central and South Eastern Europe – a Historical Review", *Romanian Journal of Neurology*, vol XV, No. 3, 2015, 111 – 118 ISSN 1843-814 | e-ISSN 2069-6094
- 2012
- Cornea R, Cimpean A.M, Simu M.A., **Cornea A.**, Suci C, Raica M. „Clinical, morphological and immunohistochemical characterization of a recurrent B1 type thymoma” *Rom J Morphol Embryol.* 2012; 53(3):639-
- Presentations
- 2016
- M. Simu, A. **Cornea**, C. Dijmarescu, Date epidemiologice privind scleroza multipla in zona de Vest a Romaniei. Conferinta Nationala de Scleroza Multipla, Editia XI, 17 - 18 (prezentare)
- Poster (Abstracts)
- 2020
- Militaru, M; Iurciuc, S; Turi, V; Cornea, A; Simu, MA Militaru, AG The role of vascular risk factors and determination of vascular remodeling parameters in patients with acute lymphoblastic leukemia EUROPEAN JOURNAL OF NEUROLOGY Volume: 27 Pages: 815-815 Supplement: 1 Meeting Abstract: EPO2077 Published: MAY 2020
- 2019
- Florica Gadalean, Mihaela Simu, Adina Cheta, Amalia **Cornea**, Cecilia Rosca, Florina Parv, Luciana Marc, Adalbert Schiller, SP337; "THE EXPANDED DISABILITY STATUS SCALE AS AN INDEPENDENT PREDICTOR FOR ESTIMATED GLOMERULAR FILTRATION RATE DECLINE IN MULTIPLE SCLEROSIS PATIENTS", *Nephrology Dialysis Transplantation*, Volume 34, Issue Supplement_1, June 2019, gfz103.SP337, <https://doi.org/10.1093/ndt/gfz103.SP337>
- 2016
- A. **Cornea**, R. Tudor, A. Petre, Lea Pillay, M. Simu – „Incidența declinul cognitiv la pacienții cu scleroză multiplă aflați în tratament imunomodulator”(poster)
- 2015
- A. **Cornea**, R. Tudor, A. Petre, A. Stoian, M. Simu. Multiple Sclerosis Demographic Data in Timis County Throught Years 2009 – 2014., The 13th Congress of the Romanian Society of Neurology, Bucharest, 2015 (poster)
 - R Joikits, A. **Cornea**, R. Tudor, C. Roșca, B Văduva, A. Stăiculescu, D. Chirileanu, M. Simu, Peripheral Polyneuropathy in Advanced Parkinson Disease Patients Treated with Continuous Duodenal Infusion of Levodopa. The 13th Congress of the Romanian Society of Neurology, Bucharest, 2015 (poster)
 - A. **Cornea**, R. Tudor, A. Petre, M. Simu, Clinical Characteristics of Spasticity in Multiple Sclerosis Treated Patients. The 13th Congress of the Romanian Society of Neurology, Bucharest, 2015 (poster)

2013

- **Cornea A, Rosca EC, Tudor R, Pop R, Simu M.A.**, "Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin", Romanian Journal of Neurology 2013, 1843-8148

Projects

- **2013 - 2015**
- Contract nr. POSDRU/159/1.5/S/136893 2007 – 2013
- Parteneriat strategic pentru creșterea calității cercetării științifice din universitățile medicale prin acordarea de burse doctorale și postdoctorale - DocMed.net_2.0"

Clinical Studies

- Subinvestigator in Study Y-79-52120-166, "An international observational prospective Study on long-term response to botulinum toxin type a (BoNT-A)injections in subjects suffering from idiopathic cervical dystonia (CD) pharmaco-economic impact", 2015 - 2017
- Subinvestigator in the study: "LAQ-MS-305, "A multinational, multicenter, randomized Double-blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Laquinimod (0.6mg / day or 1,2 mg /day)in Subjects With Relapsing Remitting Multiple Sclerosis" 2014 - 2017
- Subinvestigator in the study: "A Phase 2/3, multi-center, randomized, double-blind, placebo-controlled (part A) and double-blind, double-dummy, active-controlled (part B), Parallel Group Study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients", 2013 ongoing
- Subinvestigator in the study: "Multicenter, randomized, double-blind, placebo-controlled, Parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis" 2009 - ongoing (extension)
- Subinvestigator in the study: "A Phase III, multicentre, randomized, parallel-group, double-blinded, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis" 2011 - ongoing
- Subinvestigator in the study: RPC01-201-Part A - „A Phase 2/3, multicenter, randomized, double-blind, placebo-controlled (part A) and double-blind, double-dummy, active-controlled (part B), parallel-group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclerosis patients", 2013 ongoing
- Subinvestigator in the study: MS-GA-301, "A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design", 2012 - 2017
- Subinvestigator in the study: SYN115-CL02 - „A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN 115 as adjunctive therapy in levodopa-treated Parkinson´s subjects with end of dose wearing off " 2012 - 2013
- Subinvestigator in the study: CBAF312A2304 - „A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod(BAF312) in patients with secondary progressive multiple sclerosis" 2012
- Subinvestigator in the study: "Open-Label Trial to Determine The Long-Term Safety of Safinamide in Parkinson Disease Patients"(Merk Serono/ Serono International SA)
 - Subinvestigator in the study: "A Multicenter, Double-Blind, Randomised, Placebo-Controlled, Extension Study to Assess Long Term-Safety And Efficacy of Two Fixed Doses of Ralfinamide (160 Or 320 Mg/Day) In Patients With Chronic Neuropathic Low Back Pain (Merk Serono/ Serono International SA)
- Subinvestigator in the study: "A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS" (Merk Serono/ Serono International SA)
- Subinvestigator in the study: "A Multicenter, Randomised, Rater-Blind, Parallel-Group, Active-Controlled to Evaluate Benefits of Switching Therapy (Glatiramer Acetate Or Interferon Beta 1a) And Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis" (Biogen Idec)
- Subinvestigator in the study: "A Multicenter, Double-Blind, Randomised, Parallel-Group Performed in Subjects with Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy Safety and Tolerability of Glatiramer Acetate Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-Blind Design" (Teva Pharmaceutical Industries)